Tiziana Life Sciences PLC (NASDAQ:TLSA)

2.46
BATS BZX Real-Time Price
As of 2:26pm ET
 -0.04 / -1.60%
Today’s Change
0.62
Today|||52-Week Range
12.17
+127.78%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$241.3M

Company Description

Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.

Contact Information

Tiziana Life Sciences Plc
55 Park Lane
London Greater London W1K 1NA
P:442074952379
Investor Relations:

Employees

Shareholders

Other institutional10.70%
Mutual fund holders0.33%
Individual stakeholders--

Top Executives

Kunwar ShailubhaiCEO, Executive Director & Chief Scientific Officer
Tiziano LazzarettiChief Financial Officer
Vaseem A. PalejwalaDirector-Clinical Operations
Jules S. JacobSenior Director-Non-Clinical Development
P.J. CooperSecretary